Investment Analysts’ Recent Ratings Updates for Illumina (ILMN)

Illumina (NASDAQ: ILMN) has recently received a number of price target changes and ratings updates:

• 5/14/2026 – Illumina is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $170.00 price target on the stock.
• 5/14/2026 – Illumina was upgraded by Royal Bank Of Canada to “moderate buy”.
• 5/14/2026 – Illumina was upgraded by Daiwa Securities Group Inc. from “neutral” to “outperform”. They now have a $155.00 price target on the stock.
• 5/9/2026 – Illumina was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 5/4/2026 – Illumina had its price target raised by Citigroup Inc. from $80.00 to $95.00. They now have a “sell” rating on the stock.
• 5/1/2026 – Illumina had its “outperform” rating reaffirmed by Evercore Inc.
• 5/1/2026 – Illumina had its price target lowered by Canaccord Genuity Group Inc. from $150.00 to $140.00. They now have a “hold” rating on the stock.
• 5/1/2026 – Illumina had its price target raised by Barclays PLC from $110.00 to $122.00. They now have an “underweight” rating on the stock.
• 5/1/2026 – Illumina had its price target raised by JPMorgan Chase & Co. from $120.00 to $125.00. They now have a “neutral” rating on the stock.
• 4/29/2026 – Illumina was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.

Insiders Place Their Bets

In related news, Director Keith A. Meister sold 104,393 shares of the stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $145.34, for a total value of $15,172,478.62. Following the completion of the sale, the director directly owned 3,500,048 shares of the company’s stock, valued at approximately $508,696,976.32. This represents a 2.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the completion of the sale, the senior vice president directly owned 15,056 shares of the company’s stock, valued at $2,093,386.24. The trade was a 4.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 330,160 shares of company stock valued at $48,028,308 over the last three months. 2.90% of the stock is currently owned by insiders.

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.